Masthead
 

Custom Search
ADVERTISEMENT
Today's Health Photos
LONDON (Reuters) - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's lung drugs.

(Reuters) - U.S. health insurer Humana Inc said on Wednesday that second-quarter profit fell due to investments in the exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments.

FREETOWN (Reuters) - The doctor leading Sierra Leone's fight against the worst Ebola outbreak on record died from the virus on Tuesday, the country's chief medical officer said.

(Reuters) - U.S. health insurer WellPoint Inc said on Wednesday that profit fell in the second quarter, partly because of some higher administrative costs stemming from the healthcare reform law and new fees, but it still came in ahead of Wall Street estimates.

WASHINGTON D.C. (Reuters) - Home genetics startup 23andMe has secured a $1.4 million two-year grant from the National Institutes of Health (NIH) to build survey tools and expand its gene database.

(Reuters) - Regeneron Pharmaceuticals Inc said the U.S. Food and Drug Administration has approved the expanded use of its eye drug Eylea for the treatment of diabetic macular edema.

FREETOWN (Reuters) - The doctor leading Sierra Leone's fight against the worst Ebola outbreak on record died from the virus on Tuesday, the country's chief medical officer said.

(Reuters) - Pfizer Inc , which in May abandoned its $118 billion bid for AstraZeneca Plc , on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals.

NEW YORK (Reuters Health) - People who arrive at the hospital with a heart attack during business hours are more likely to survive than those who show up on weeknights, weekends or holidays, according to a new study.

BUDAPEST/PARIS (Reuters) - Hungary's competition watchdog GVH has raided the Hungarian headquarters of French drug maker Sanofi as the first step of proceedings against the firm for suspected abuse of its dominant market position.

ADVERTISEMENT
Log into your Thames Valley Portal
Video
loading